CRSP Stock Annual Cash Flow. Download in Excel
CRISPR Therapeutics AG
CRSP 
NSD
Sector: Healthcare
Industry: Biotechnology
46.29
USD
-0.97
(-2.05%)
Previous close: 47.26 Open: 47.21 Bid: 46.0 Ask: 46.8
52 week range
43.42 91.10
Mkt Cap: 4,009 M Avg Vol (90 Days): 1,283,124
Last updated: Friday 22nd November 2024
Financials
CRSP Cash Flow
Annual
| Invalid date | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | Dec-23 | |
|---|---|---|---|---|---|---|---|---|---|
| (Increase) Decrease in other current liabilities | 2 M | -20 M | -47000.0 | -20 M | -9 M | -6 M | -3 M | 6 M | |
| (Increase) Decrease in other working capital | 8 M | ||||||||
| (Increase) Decrease in payables | 4 M | -831000.0 | 12 M | 5 M | 26 M | 38 M | 5 M | -20 M | |
| (Increase) Decrease in receivables | -3 M | 531000.0 | 3 M | -11000.0 | -45000.0 | -161000.0 | 305000.0 | -200 M | |
| Acquisitions | -100000.0 | -2 M | |||||||
| CapitalExpenditureReported | 3 M | 8 M | 3 M | 7 M | 18 M | 82 M | 37 M | 9 M | |
| Cash at beginning of period | 156 M | 319 M | 243 M | 460 M | 949 M | 1,185 M | 940 M | 224 M | |
| Cash at end of period | 376 M | 243 M | 460 M | 949 M | 1,185 M | 940 M | 224 M | 401 M | |
| Cash flow | -53 M | -70 M | -96 M | 57 M | -238 M | 539 M | -496 M | -260 M | |
| CashFlowFromContinuingInvestingActivities | 29 M | -8 M | -3 M | 1 M | -541 M | -1,035 M | -259 M | 375 M | |
| ChangeInAccountPayable | 4 M | -831000.0 | 12 M | 5 M | 26 M | 38 M | 5 M | -20 M | |
| ChangeInPayablesAndAccruedExpense | 4 M | -831000.0 | 12 M | 5 M | 26 M | 38 M | 5 M | -20 M | |
| ChangeInPrepaidAssets | -1 M | -4 M | -3 M | -33 M | 17 M | -14 M | 2 M | 23 M | |
| ChangeInWorkingCapital | 10 M | -25 M | 11 M | -48 M | 34 M | 17 M | 5 M | -191 M | |
| ChangesInAccountReceivables | -3 M | 531000.0 | 3 M | -11000.0 | -45000.0 | -161000.0 | 305000.0 | -200 M | |
| CommonStockPayments | -57000.0 | ||||||||
| Depreciation | 925000.0 | 3 M | 4 M | 5 M | 9 M | 18 M | 24 M | 20 M | |
| Depreciation unreconciled | 925000.0 | 3 M | 4 M | 5 M | 11 M | 18 M | 24 M | 20 M | |
| DepreciationAndAmortization | 925000.0 | 3 M | 4 M | 5 M | 11 M | 18 M | 24 M | 20 M | |
| EarningsLossesFromEquityInvestments | 4 M | 5 M | |||||||
| Effect of exchange rate changes | -235000.0 | 41000.0 | -22000.0 | 15000.0 | 40000.0 | -11000.0 | -80000.0 | 73000.0 | |
| FinancingCashFlow | 244 M | 3 M | 316 M | 431 M | 1,016 M | 251 M | 39 M | 63 M | |
| Free cash flow | -56 M | -78 M | -99 M | 50 M | -257 M | 457 M | -533 M | -270 M | |
| Issuance of capital stock | 89 M | 307 M | 415 M | 982 M | 213 M | 970000.0 | 33 M | ||
| IssuanceOfCapitalStock | 89 M | 307 M | 415 M | 982 M | 213 M | 970000.0 | 33 M | ||
| IssuanceOfDebt | 35 M | ||||||||
| Net cash from financing activities | 244 M | 3 M | 316 M | 431 M | 1,016 M | 251 M | 39 M | 63 M | |
| Net cash from investing activities | 29 M | -8 M | -3 M | 1 M | -541 M | -1,035 M | -259 M | 375 M | |
| Net cash from operating activities | -53 M | -70 M | -96 M | 57 M | -238 M | 539 M | -496 M | -260 M | |
| Net change in cash & cash equivalents | 220 M | -76 M | 217 M | 489 M | 237 M | -246 M | -716 M | 177 M | |
| Net income from continuing operations | -23 M | -68 M | -165 M | 67 M | -349 M | 378 M | -650 M | -154 M | |
| NetBusinessPurchaseAndSale | -100000.0 | -2 M | |||||||
| NetCommonStockIssuance | 89 M | 307 M | 415 M | 982 M | 213 M | 970000.0 | 33 M | ||
| NetForeignCurrencyExchangeGainLoss | 2000.0 | -9000.0 | |||||||
| NetInvestmentPropertiesPurchaseAndSale | 33 M | -500000.0 | 8 M | -523 M | -954 M | -221 M | 387 M | ||
| NetInvestmentPurchaseAndSale | 33 M | -500000.0 | 8 M | -523 M | -954 M | -221 M | 387 M | ||
| NetIssuancePaymentsOfDebt | 35 M | ||||||||
| NetLongTermDebtIssuance | 35 M | ||||||||
| NetPPEPurchaseAndSale | -3 M | -8 M | -3 M | -7 M | -18 M | -82 M | -37 M | -9 M | |
| NetPreferredStockIssuance | 122 M | ||||||||
| Operating (gains) losses | -11 M | -9000.0 | 4 M | 5 M | |||||
| Other financing charges net | -2 M | ||||||||
| Other investing changes net | 33 M | -4000.0 | 8 M | ||||||
| Other non-cash items | -29 M | 20 M | 50 M | 27 M | 66 M | 126 M | 126 M | 65 M | |
| PreferredStockIssuance | 122 M | ||||||||
| ProceedsFromStockOptionExercised | 34000.0 | 3 M | 9 M | 16 M | 34 M | 38 M | 38 M | 30 M | |
| Purchase of Float term investments | -500000.0 | -594 M | -1,509 M | -1,418 M | -1,066 M | ||||
| Purchase of property plant & equipment | -3 M | -8 M | -3 M | -7 M | -18 M | -82 M | -37 M | -9 M | |
| Purchase of short term investments | 35 M | ||||||||
| PurchaseOfInvestment | -500000.0 | -594 M | -1,509 M | -1,418 M | -1,066 M | ||||
| PurchaseOfPPE | -3 M | -8 M | -3 M | -7 M | -18 M | -82 M | -37 M | -9 M | |
| Repurchase of capital stock | -57000.0 | ||||||||
| Revenue per share | 2 M | 14 M | |||||||
| Sale of short term investments | 71 M | 556 M | 1,196 M | 1,453 M | |||||
| SaleOfInvestment | 71 M | 556 M | 1,196 M | 1,453 M | |||||
| StockBasedCompensation | 11 M | 19 M | 35 M | 44 M | 66 M | 102 M | 98 M | 81 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS is a complete Excel stock solution
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel
MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.
I like to access historical closing prices on a particular date. That makes tracking performance easy.